Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...
What is HC Wainwright’s Forecast for CRVS FY2025 Earnings?
Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...
ETF Daily News6d
What is HC Wainwright’s Estimate for CRVS FY2028 Earnings?
Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the ...
Benzinga.com2d
FDA Calendar
Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...